Cronos Group Inc vs Rocket Lab USA Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Rocket Lab USA Inc trades at $68.2 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 37.1× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Rocket Lab USA Inc for 29 Days on average.
| CRON | RKLB | |
|---|---|---|
Market Cap | $1.18B | $43.74B |
Volume | 968,037 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $3.55 | $150.23 |
52-Week Low | $2.30 | $39.48 |
Typical Hold Time | 22 Days | 29 Days |
Enterprise Value | $387.62M | $41.57B |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.
Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →